Altimmune Inc (ALT)
Healthcare
Biotechnology
2.80 $
-4.7%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Altimmune Inc (ALT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 84.4% of the shares are freely tradable; institutional investors hold 57.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
57.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.4%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
84.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
21.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
195Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 6.58 | 12,795,277 | +31.9 | 03/31/2026 |
| Vanguard Group Inc | 4.88 | 9,491,159 | +48.9 | 12/31/2025 |
| State Street Corp | 3.67 | 7,145,550 | +39.6 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.91 | 5,658,049 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 2.77 | 5,382,002 | +0.0 | 03/31/2026 |
| Marshall Wace Asset Management Ltd | 2.07 | 4,017,901 | +335.4 | 03/31/2026 |
| Millennium Management LLC | 1.68 | 3,258,191 | +1,471.1 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 3.18 | 6,183,071 | +50.5 | 04/30/2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.45 | 4,755,132 | -0.6 | 05/31/2026 |
| iShares Russell 2000 ETF | 1.61 | 3,132,215 | +0.9 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.